Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Japan
jRCT2061240117Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in glabellar furrowing (4 arms), sponsored by AbbVie Inc. Primary endpoints: Investigator-rated FHL severity 'None' or 'Mild' at maximum contraction at Day 30 and Adverse events. Started Jan 2025; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on jRCT2061240117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240117.